SCHEMBL6502082

SCHEMBL6502082

COC(=O)c1ccc(-c2ccccc2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
NR4A2 P43354 2/20 0.55
HDAC8 Q9BY41 2/20 0.52
SLC6A3 Q01959 3/20 0.51
SLC6A4 P31645 1/20 0.51
EGFR P00533 1/20 0.51
ACLY P53396 2/20 0.50
HDAC6 Q9UBN7 1/20 0.49
ESR2 Q92731 1/20 0.49
ERCC5 P28715 2/20 0.48
FEN1 P39748 2/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884923 0.91 PDK2 (0.57) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL23226657 0.87 PDK2 (0.51) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL10623435 0.86 ESR2 (0.52) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1761427 0.85 GAA (0.54) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL23380259 0.84 PDK2 (0.50) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL14252250 0.84 NR4A2 (0.59) MEN1KMT2ALMNASMN1; SMN2KDM4E
SCHEMBL70440 0.84 NR4A2 (0.59) MEN1KMT2ALMNASMN1; SMN2KDM4E
SCHEMBL5924701 0.84 PDK2 (0.58) PDK2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL5059050 0.83 TSHR (0.54) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL10004832 0.81 PDK2 (0.56) PDK2MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
EP-3478672-B1 BIARYLMETHYL HETEROCYCLES UNIV MONTREAL (CA) 2024-04-10 EP disclosed
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES Université de Montréal (CA) 2023-02-09 US disclosed
US-11407733-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-09 US disclosed
US-20190202808-A1 BIARYLMETHYL HETEROCYCLES BRISTOL-MYERS SQUIBB COMPANY 2019-07-04 US disclosed
CN-1301964-C Inhibitors of alpha 4-mediated cell adhesion TANABE SEIYAKU CO (JP) 2007-02-28 CN disclosed
CN-1228327-C Carboxylic acid derivatives and drugs containing the same EISAI CO LTD (JP) 2005-11-23 CN disclosed
US-6884821-B1 Carboxylic acid derivatives and drugs containing the same EISAI CO., LTD. (JP) 2005-04-26 US disclosed
CN-1377336-A Carboxylic acid derivatives and drugs containing the same EISAI CO LTD (JP) 2002-10-30 CN disclosed
EP-1216980-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-06-26 EP disclosed
CN-1288457-A Inhibitors of & alpha, 4 mediated cell adhesion TANABE SEIYAKU CO (JP) 2001-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407733-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 PDK2 2483/4885MEN1 4154/4885KMT2A 3170/4885
US-20190202808-A1 BIARYLMETHYL HETEROCYCLES ARRB1, ADRB2, ADRB1 PDK2 2483/4885MEN1 4154/4885KMT2A 3170/4885
US-12037324-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 PDK2 2483/4885MEN1 4154/4885KMT2A 3170/4885
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES ARRB1, ADRB2, ADRB1 PDK2 2483/4885MEN1 4154/4885KMT2A 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.